Impact of angiotensin receptor blocker as antihypertensive in assessing mortality in patients of COVID-19: A single tertiary care center study.
ARB (Angiotensin II receptor blocker)
COVID − 19
ICU (intensive care unit)
mortality
Journal
Journal of education and health promotion
ISSN: 2277-9531
Titre abrégé: J Educ Health Promot
Pays: India
ID NLM: 101593794
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
06
2022
accepted:
23
08
2022
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
The angiotensin-converting enzyme 2 (ACE2) receptor, a membrane receptor present in the respiratory system, the gastrointestinal tracts, the heart, and the kidney is the entry point for SARS-CoV-2 to enter human cells. Concerns were raised about the influence of using antihypertensive drugs like angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in individuals with COVID-19 due to its tight relationship with the ACE2 receptor. The aim of this study was to investigate the impact of being on an Angiotensin Receptor Blockers (ARB) on mortality in patients consecutively diagnosed with COVID-19. This is the retrospective observational study done in all patients consecutively diagnosed with COVID-19 from January 2021 to June 2021. All related patient information and clinical data was retrieved from the hospitals electronic medical record system. In this study, out of 500 patients, 51 died, having mean age of 66.92 ± 10.85 years. 144 (28.8%) patients were on angiotensin receptor blockers as antihypertensive treatment, 142 (28.4%) having other antihypertensive and 214 (42.8%) were not on any treatment. Out of 51 Death 7 (4.9) patients were on ARBs, 15 ± 10.6 were on other medication [OR 2.31 (0.94-6.22, Use of ARB medications for the hypertensive patients who acquire COVID-19 infection has shown protective effects of such medications on COVID-19 disease severity in the term of mortality and the mortality rate among hypertensive patients on COVID-19 with ARBs/ACE inhibitors showed significant differences as compared to other antihypertensives.
Sections du résumé
BACKGROUND
BACKGROUND
The angiotensin-converting enzyme 2 (ACE2) receptor, a membrane receptor present in the respiratory system, the gastrointestinal tracts, the heart, and the kidney is the entry point for SARS-CoV-2 to enter human cells. Concerns were raised about the influence of using antihypertensive drugs like angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in individuals with COVID-19 due to its tight relationship with the ACE2 receptor. The aim of this study was to investigate the impact of being on an Angiotensin Receptor Blockers (ARB) on mortality in patients consecutively diagnosed with COVID-19.
MATERIAL AND METHODS
METHODS
This is the retrospective observational study done in all patients consecutively diagnosed with COVID-19 from January 2021 to June 2021. All related patient information and clinical data was retrieved from the hospitals electronic medical record system.
RESULTS
RESULTS
In this study, out of 500 patients, 51 died, having mean age of 66.92 ± 10.85 years. 144 (28.8%) patients were on angiotensin receptor blockers as antihypertensive treatment, 142 (28.4%) having other antihypertensive and 214 (42.8%) were not on any treatment. Out of 51 Death 7 (4.9) patients were on ARBs, 15 ± 10.6 were on other medication [OR 2.31 (0.94-6.22,
CONCLUSION
CONCLUSIONS
Use of ARB medications for the hypertensive patients who acquire COVID-19 infection has shown protective effects of such medications on COVID-19 disease severity in the term of mortality and the mortality rate among hypertensive patients on COVID-19 with ARBs/ACE inhibitors showed significant differences as compared to other antihypertensives.
Identifiants
pubmed: 37034857
doi: 10.4103/jehp.jehp_922_22
pii: JEHP-12-30
pmc: PMC10079203
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30Informations de copyright
Copyright: © 2023 Journal of Education and Health Promotion.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Clin Infect Dis. 2020 Jul 28;71(15):706-712
pubmed: 32109279
Hypertension. 2020 Aug;76(2):e15-e17
pubmed: 32493070
Clin Med (Lond). 2020 Mar;20(2):124-127
pubmed: 32139372
Heart. 2020 Oct;106(19):1519-1524
pubmed: 32611676
J Intern Med. 2021 May;289(5):688-699
pubmed: 33210357
Cureus. 2022 Feb 23;14(2):e22528
pubmed: 35345725
J Pathol. 2011 Dec;225(4):618-27
pubmed: 22009550
JAMA. 2021 Apr 27;325(16):1620-1630
pubmed: 33734299
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Indian J Crit Care Med. 2022 Jan;26(1):39-42
pubmed: 35110842
Int Urol Nephrol. 2019 Oct;51(10):1815-1822
pubmed: 31332700
Anatol J Cardiol. 2020 Jul;24(1):21-29
pubmed: 32628137
Int J Cardiol Heart Vasc. 2020 Dec;31:100660
pubmed: 33083516
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004
Eur J Heart Fail. 2020 Jun;22(6):967-974
pubmed: 32485082
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343